Clinical trials of rheumatoid arthritis drug Kevzara – as a coronavirus treatment – has been expanded by Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) to patients outside the U.S.
The trial, expected to enroll about 300 patients,
will recruit hospitalized patients from several countries who are
severely or critically ill with COVID-19.
Hopes are that the drug that can suppress a
so-called cytokine storm, which happens when the immune system
overreacts and attacks the body’s organs.
https://seekingalpha.com/news/3556140-sanofi-regeneron-expand-testing-of-kevzara
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.